VSV-GP

Clinical research has shown that the current wave of checkpoint-centric therapies is beneficial in those patients with immunologically active and highly-mutated so-called ‘hot’ tumors. But they have limited efficacy in those tumor types that lack these properties, commonly known as ‘cold’ tumors. Boehringer Ingelheim has made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers. We are developing complementary platforms including T-cell engagers, oncolytic viruses, cancer vaccines, which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.

VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) is a modified vesicular stomatitis oncolytic virus. Oncolytic virus therapy is a cancer treatment approach that uses a virus that infects and breaks down cancer cells. Tumor antigens that are normally hidden from the immune system inside the cells are released, triggering an immune response to fight the tumor.

This compound is under investigation, further information will be available soon.